News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Markets Mojo Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 4.30% in Inhibikase Therapeutics (IKT), totaling 5,810,487 shares as of June 30, 2026. This stake includes 3,108,624 shares acquirable through convertible securities within sixty days. The …
Sands Capital Life Sciences Pulse Fund II, L.P., along with related entities, has reported a beneficial ownership of 9.3% in Inhibikase Therapeutics, Inc. This stake includes 13,018,965 shares of common stock and substantial warrants for an additional 15.5 million shares, although these warrants are …
Playtika reported Q2 2026 earnings with revenue up 5% year-over-year to $731.1 million and adjusted EBITDA increasing 23.4% to $206.1 million. The company strategically front-loaded marketing investments in Q1, leading to a planned step-down in spend and significant margin expansion in Q2. Despite a …
Oppenheimer has reiterated its Buy rating on Inhibikase Therapeutics (IKT.US), maintaining a target price of $5. This indicates continued confidence from the firm in the company's prospects.
Playtika Holding Corp (PLTK) stock recently hit a 52-week low of $2.48, reflecting a significant drop of over 31% in the past week and a 33.86% decline over the year. Despite this, the company offers a 15% dividend yield and is considered undervalued relative …
Inhibikase Therapeutics announced its Q2 2026 financial results, reporting a net loss of $19.6 million and $159.0 million in cash and marketable securities. The company highlighted significant progress in its Phase 3 IMPROVE-PAH study for IKT-001, including regulatory approvals in 26 countries and recent …
This article identifies three tech and telecom stocks—Playtika Holding Corp (PLTK), The Trade Desk Inc (TTD), and Applovin Corp (APP)—as oversold based on their Relative Strength Index (RSI) being below 30. All three companies recently experienced significant stock price declines, with Playtika and The …
Citi analyst Jason Bazinet has lowered the price target for Playtika Holding Corp. (PLTK) to $4.50. The article is a premium piece, requiring a subscription to read further details.
Inhibikase Therapeutics reported a Q2 2026 net loss of $19.6 million, or $(0.11) per share, which met analyst estimates but widened from the previous year due to increased R&D spending for its Phase 3 PAH program. The company also raised $50 million through a …
Playtika Holding Corp. (NASDAQ: PLTK) shares dropped 28% after its Q2 results showed a 25% EPS miss, despite revenue surpassing estimates. Following this, analysts maintained revenue forecasts but significantly cut EPS estimates for 2026, from US$0.48 to US$0.40 per share, while the consensus price …
Playtika Holding Corp.'s CFO, Lee Tae, reported a Form 4 transaction involving the disposition of 1,241 shares of common stock on August 7, 2026. These shares, valued at $2.94 each, were delivered or withheld to cover exercise price or tax liability. After the transaction, …
Search by ticker symbol or company name and select a result to open its chart.